Advancing a Framework for Regulatory Use of Real-World Evidence: When Real Is Reliable
Article
May 04, 2018

By: Nancy Dreyer

There is growing interest in regulatory use of randomized pragmatic trials and noninterventional real-world (RW) studies of effectiveness and safety, but there is no agreed-on framework for assessing when this type of evidence is sufficiently reliable. Rather than impose a clinical trial–like paradigm on RW evidence, like blinded treatments or complete, source-verified data, the framework for assessing the utility of RW evidence should be grounded in the context of specific study objectives, clinical events that are likely to be detected in routine care, and the extent to which systematic error (bias) is likely to impact effect estimation. Whether treatment is blinded should depend on how well the outcome can be measured objectively.

Contact Us
Contact Us

Email Us

Interested in learning more about how IQVIA can create solutions to help you drive healthcare forward?

Call Us

We're available during standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our toll-free list.